News

The FDA recently released guidelines expanding clinical trial eligibility for investigational cancer drugs for pediatric patients.

During his presentation, Michael A. Postow, MD, briefly reviewed the latest updates with immunotherapy and other targeted treatments in melanoma reported during the 2020 ASCO Virtual Scientific Program.

Efbemalenograstim alpha (F-627) has demonstrated strong and lasting benefit when used as a treatment for chemotherapy-induced neutropenia in patients with breast cancer, meeting the primary and secondary end points of a phase 3 study.

The FDA has granted priority review to a new supplemental biologics license application for pembrolizumab monotherapy as a treatment for adult patients with relapsed/refractory classical Hodgkin lymphoma.

We want to hear from nurses about your comfort in having end-of-life discussions.

Each Friday, Oncology Nursing News poses a question on Facebook, Twitter, and Instagram and invites readers to share their thoughts and experiences with each other. Here’s what readers had to say about the thoughtful comments of their patients, and how their job has changed their outlook on life.

Dexamethasone, a corticosteroid traditionally used in cancer treatment, may be beneficial in treating patients with the novel coronavirus 2019 (COVID-19).

Liquid biopsy with circulating tumor DNA could help alleviate some of the challenges of tissue biopsy in prostate cancer, and in doing so, lead to a better precision medicine model in the field.

The FDA has issued a clinical hold on the phase 1 MELANI-01 trial evaluating the CAR T-cell product UCARTCS1A in the treatment of patient with relapsed/refractory multiple myeloma, according to Cellectis, the manufacturer of the product.

The drug combination can be taken orally, at home.

Patients with metastatic HER2-positive breast cancer who later develop central nervous system (CNS) metastases comprise a large population of all patients with breast cancer, and there continue to be an unmet need for this subgroup, explained Brian Czerniecki, MD, PhD.

LaTour was the emcee for the Extraordinary Healer Award Dinner, which honors the work of oncology nurses and is hosted every year at the Oncology Nursing Society Annual Congress. She was also a co-founder of CURE Magazine, as well as an author and breast cancer survivor. She died on June 19.

Fam-trastuzumab deruxtecan-nxki (Enhertu) could provide patients with metastatic non–small cell lung cancer (NSCLC) who harbor HER2 exon 20 insertion mutations and high HER2 expression a more specific and less toxic treatment compared with platinum doublet chemotherapy. However, the jury is still out on whether the agent will be pursued as an alternative frontline therapy and in both patient subsets.

The combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) demonstrated comparable clinical activity and safety versus sorafenib (Nexavar) in older and younger patients with previously untreated, unresectable hepatocellular carcinoma (HCC).

CAR T-cell therapies have represented an exciting breakthrough in the treatment of patients with hematologic malignancies, according to Natalie Sophia Grover, MD; however, investigators are just scratching the surface of the potential of this modality, and work is needed to expand this approach to other diseases and solid tumors.

A new drug application (NDA) has been submitted to the FDA for pralsetinib (BLU-667) for the treatment of patients with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) and RET fusion–positive thyroid cancers, according to an announcement from Blueprint Medicines, the developer of the drug.

Each month, we take a look back at the most popular Oncology Nursing News stories. Here are the top 5 stories from June 2020.

Following the arrival of the coronavirus disease 2019 pandemic, St. Jude Children's Research Hospital launched the first Global COVID-19 Observatory and Resource Center for Childhood Cancer.

The FDA has approved pembrolizumab (Keytruda) for the first-line treatment of patients with unresectable or metastatic microsatellite instability–high or mismatch repair deficient colorectal cancer. This marks the first immunotherapy approved for this patient population as a first-line treatment and which is administered to patients without also giving chemotherapy.

The FDA approved subcutaneous Phesgo – a combination of pertuzumab (Perjeta), trastuzumab (Herceptin), and hyaluronidase–zzxf – for the treatment of patients with metastatic HER2-positive breast cancer, as well as early-stage HER2-positive breast cancer, as selected by an FDA-approved companion diagnostic test.

Patients with breast cancer who harbor multiple PIK3A-mutant tumors achieved a higher clinical benefit from PI3Kα inhibition compared with single mutant tumors according to response analysis data from the SANDPIPER trial.

The pandemic has reduced cancer screening and diagnostic testing as well as clinical trials and research.

Nivolumab plus ipilimumab showed an improvement in relapse-free survival for this patient population.

The FDA has approved pembrolizumab (Keytruda) or patients with recurrent or metastatic cutaneous squamous cell carcinoma that is not curable by surgery or radiation.

Pembrolizumab (Keytruda) demonstrated modest clinical activity in patients with advanced recurrent ovarian cancer, according to final results of the phase 2 KEYNOTE-100 trial that were presented during the 2020 ASCO Virtual Scientific Program.

The ongoing coronavirus disease 2019 (COVID-19) pandemic has magnified the value of real-world data (RWD) in oncology. The FDA is presently spearheading several initiatives aimed at refining the role of RWD in cancer care to guide clinical trial development, procure answers to pressing clinical questions, and support regulatory decisions for in vitro diagnostics.

The FDA has had a busy couple of weeks, approving new agents to treat a variety of cancers.

The combination of atezolizumab (Tecentriq) plus carboplatin/etoposide continued to demonstrate an improvement in overall survival (OS) versus chemotherapy alone as a frontline treatment for patients with extensive-stage small cell lung cancer (ES-SCLC), regardless of PD-L1 and blood tumor mutational burden (bTMB) status.